EMPHASIS-HF Mortality Reduction Index
Patient profile
Masukkan parameter klinis untuk melihat ilustrasi kalkulasi. Ini bukan model prognostik tervalidasi.
Clinical context
EMPHASIS-HF evaluated eplerenone added to recommended therapy in patients with chronic systolic heart failure and mild symptoms. The primary endpoint was cardiovascular death or hospitalization for heart failure.
Key trial findings
| Outcome | Eplerenone | Placebo | Effect |
|---|---|---|---|
| Primary composite endpoint | 18.3% | 25.9% | HR 0.63 (95% CI 0.54–0.74) |
| Death from any cause | 12.5% | 15.5% | HR 0.76 (95% CI 0.62–0.93) |
| Death from cardiovascular causes | 10.8% | 13.5% | HR 0.76 (95% CI 0.61–0.94) |
Safety considerations
EMPHASIS-HF reported serum potassium above 5.5 mmol/L in 11.8% of participants receiving eplerenone and 7.2% receiving placebo. Assess renal function and potassium, and follow current prescribing information and applicable heart-failure guidance when treating patients.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.